ReviewFood science of animal resources2026
Deer antler velvet as a multifunctional natural resource for biomedical and nutraceutical applications.
Review in Food science of animal resources, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Deer antler velvet (DAV), harvested from the growing antlers of deer, is a biologically dynamic animal-derived material that has attracted scientific interest due to its regenerative characteristics and complex biochemical composition. DAV contains proteins, peptides, growth-associated factors, polysaccharides, amino acids, lipids, and minerals, which have been investigated across diverse experimental systems. Although numerous studies report immunomodulatory, antioxidant, regenerative, neuroprotective, and musculoskeletal-related effects, the strength of evidence varies considerably, with the majority of data derived from in vitro and animal models and comparatively limited well-controlled human trials. This review provides a critical and mechanism-oriented synthesis of DAV research, three analytical perspectives: (1) compositional variability and its implications for standardization and reproducibility; (2) differentiation between the hierarchy of evidence distinguishing experimental plausibility from clinically validated outcomes; and (3) translational considerations, including bioavailability, pharmacokinetics of growth-associated components, and regulatory constraints. Reported molecular mechanisms converge on established pathways governing growth regulation, redox balance, immune modulation, and tissue remodeling; however, the systemic relevance of orally administered bioactive constituents, particularly growth factors such as IGF-1, remains incompletely defined. While DAV demonstrates biological activity across multiple preclinical models and limited human studies, critical challenges persist in dose standardization, long-term safety evaluation, clinical validation, and international regulatory harmonization. Future progress will depend on the establishment of defined compositional markers, rigorous pharmacokinetic assessment, and well-powered randomized controlled trials. By integrating compositional analysis, mechanistic evaluation, and translational feasibility, this review clarifies both the potential and the current limitations of DAV in biomedical and nutraceutical applications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.